1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes”
Communities adapt and reinterpret the landscape of the former Stutthof concentration camp, balancing memory and identity.
60 citations
,
January 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying a specific inhibitor lightens skin and hair color.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
February 2023 in “Journal of medical primatology” Pair housing reduces stress behaviors and health issues in quarantined rhesus macaques.
March 2023 in “Jurnal Ilmiah Medicamento” The hair tonic from Usada Bali plants increased hair growth without irritating the skin.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
April 2023 in “Journal of Investigative Dermatology”
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
9 citations
,
September 2019 in “Clinical Cosmetic and Investigational Dermatology” Cal/BD aerosol foam effectively treats scalp psoriasis, improving symptoms and patient satisfaction.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
21 citations
,
May 2014 in “Toxicological Sciences” Toluene diisocyanate exposure can cause immune sensitization by interacting with proteins in hair follicles and sebaceous glands.
January 2026 in “Food Science and Human Wellness” Krill oil may help reduce prostate enlargement and growth.
January 2007 in “Edward Elgar eBooks” TSPO might help treat anxiety and depression.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology”
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
February 2025 in “Iranian journal of pharmaceutical research” 4 citations
,
November 2001 in “Journal of Neuropsychiatry” Divalproex sodium can sometimes worsen behavior in some patients.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
1 citations
,
March 2025 in “Skin Appendage Disorders” Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
December 2011 in “Thorax” People from iodine-deficient areas are more likely to develop hypothyroidism when treated for multi-drug resistant tuberculosis.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.